Inclusion Criteria:

1. The presence of primary oral cavity, primary pharyngeal, primary laryngeal, salivary
gland, limited recurrent and second primary tumors must be confirmed by histological
examination of a tissue sample (e.g., biopsy) obtained within 2 months of the subject
receiving the study treatment.

2. The length of the longest diameter of the study lesion must be < 5 cm and the
calculated treatment volume (tumor volume plus a 0.5 cm margin around the tumor) for
the study lesion [where treatment volume = 0.5 (a+1) (b+1)2 and where a = length of
the longest diameter (cm), b = the next longest diameter perpendicular to "a" (cm)]
must be < 60.0 cm3.

3. Age: 18 years or older.

4. Male or female.

5. Men and women of childbearing potential must be using Investigator prescribed
contraceptive methods while undergoing protocol related therapy.

6. Baseline performance status: ECOG 0-2:

- Grade 0: Fully active, able to carry on all pre-disease performance without
restriction.

- Grade 1: Restricted in physically strenuous activity but ambulatory and able to
carry out work of a light or sedentary nature, e.g., light house work, office
work.

- Grade 2: Ambulatory and capable of all self-care, but unable to carry out any
work activities. Up and about more than 50% of waking hours.

7. Life expectancy of at least 6 months.

8. Subjects must sign a written Informed Consent prior to receiving any study procedures
or treatments.

Exclusion Criteria:

1. Subjects with tumors suspected of involving a 50% or greater encasement of a blood
vessel as measured by magnetic resonance imaging (MRI) or computed tomography (CT)
scan.

2. Subjects with tumors having bone invasion.

3. Subjects with hypersensitivity to bleomycin.

4. Subjects who have received or will exceed a total lifetime dose of bleomycin greater
than 400 units.

5. Subjects deemed unsuitable for general anesthesia.

6. Subjects with a significant history of emphysema or pulmonary fibrosis.

7. Subjects with indwelling cardiac pacemakers who cannot tolerate a period with
pacemaker turned off.

8. Subjects with a history of uncontrolled cardiac arrhythmia.

9. Women who are pregnant, or are nursing. Women must have a negative pregnancy test
(urine pregnancy tests are acceptable) within 7 days of study treatment.